Request Trial
yanlev-shutterstock-com-1
YanLev / Shutterstock.com
3 December 2015AmericasGerard Norton and Michael Montgomery

To dance or not to dance: biosimilar strategies post Amgen v Sandoz

The Biologics Price Competition and Innovation Act (BPCIA) is a landmark piece of legislation signed into law by the Obama administration in 2009. The BPCIA provides for a regulatory approval pathway for biosimilar products, which are like generic pharmaceuticals in that they are based on already approved ‘name brand’ biologics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Novartis win blocks generics relitigating $7.8bn heart drug patent
22 January 2026   A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.
Americas
Rooted rights: Lessons from plant patent infringement and invalidity cases
22 January 2026   From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Americas
Skinny labels, big stakes: SCOTUS lines up the case of the year
21 January 2026   The court’s review of a high-profile dispute could offer clarity on a grey area for pharma companies and generic drug makers, but also prompt fresh questions.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

Novartis win blocks generics relitigating $7.8bn heart drug patent
Leading the arena: WIPR identifies the top US trade secrets specialists of 2025
Rooted rights: Lessons from plant patent infringement and invalidity cases
Cadwalader global head among trio moving to Orrick
Skinny labels, big stakes: SCOTUS lines up the case of the year
$5.4bn medtech leader fails to bury a rival's patent
Senior four-partner team leaves A&O Shearman
Final call: Who are the world’s best in-house counsel?